PHNPharmanutra S.p.A.
90.50EUR+1.46%Mkt Cap: 860.81M EURP/E: 40.86Last update: 2026-05-14

Pharmanutra S.p.A., a nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internati…

loading…
Indicators:|

Key Statistics

Valuation
P/E (Trailing)40.86
P/E (Forward)29.35
PEG
P/B12.08
P/S6.20
EV/EBITDA25.71
EV/Revenue6.13
EPS (TTM)2.20
EPS (Forward)3.06
Cash Flow & Leverage
FCF Yield1.69%
FCF Margin10.49%
Operating CF19.56M EUR
CapEx (TTM)3.13M EUR
Net Debt/EBITDA-0.30
Net Debt-9.91M EUR
Technical
SMA 5077.02 (+17.5%)
SMA 20058.81 (+53.9%)
Beta
S&P 52W Chg24.23%
Avg Vol (30d)16.40K
Avg Vol (10d)20.63K
Technical Indicators
RSI (14)76.9
MACD2.4654
MACD Signal1.5211
MACD Hist.+0.9444
BB Upper88.67 EUR
BB Middle80.74 EUR
BB Lower72.81 EUR
BB Width19.64%
ATR (14)2.956 EUR
Vol Ratio (20d)0.57x
52W Range
38.7599% of range90.80
52W High90.80 EUR
52W Low38.75 EUR
Profitability
Gross Margin77.38%
EBITDA Margin23.85%
Profit Margin15.05%
Oper. Margin15.76%
ROE28.03%
ROA15.97%
Revenue Growth24.50%
Earnings Growth44.40%
Balance Sheet
Debt/Equity0.29
Current Ratio2.38
Quick Ratio2.11
Book Value/Sh7.440 EUR
Cash/Share3.029 EUR
Dividends
Fwd Div Rate1.200 EUR
Trail. Div Rate0.0000 EUR
Div. Yield1.33%
5Y Avg Yield1.44%
Payout Ratio45.45%
Ex-Div DateMay 4, 2026
Pay Date
Ownership
Shares Out.9.58M
Float3.27M
Insiders65.02%
Institutions16.14%
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)81.33 EUR
Target Range76.00 EUR86.00 EUR
# Analysts3
Company
Market Cap860.81M EUR
Enterprise Value850.90M EUR
Revenue (TTM)138.73M EUR
Gross Profit102.87M EUR
Net Income (TTM)20.00M EUR
Revenue/Share14.49 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees128
Last Price90.50 EUR
CountryIT
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINIT0005274094